Aurinia Pharmaceuticals Inc. Quarterly Operating Income (Loss) in USD from Q1 2019 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Aurinia Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2019 to Q3 2024.
Aurinia Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $11.7M.
Aurinia Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$32.7M, a 63.7% increase year-over-year.
Aurinia Pharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$91.7M, a 17.7% increase from 2022.
Aurinia Pharmaceuticals Inc. annual Operating Income (Loss) for 2022 was -$111M, a 38.3% increase from 2021.
Aurinia Pharmaceuticals Inc. annual Operating Income (Loss) for 2021 was -$181M, a 73.3% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$32.7M	$11.7M	+$28M		Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-07
Q2 2024	-$60.7M	-$1.51M	+$14.7M	+90.6%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-01
Q1 2024	-$75.4M	-$13.3M	+$16.3M	+55.2%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-02
Q4 2023	-$91.7M	-$29.7M	-$1.57M	-5.6%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-15
Q3 2023	-$90.1M	-$16.3M	-$6.76M	-71.2%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-07
Q2 2023	-$83.4M	-$16.2M	+$19.8M	+55.1%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-01
Q1 2023	-$103M	-$29.6M	+$8.3M	+21.9%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-02
Q4 2022	-$111M	-$28.1M	+$4.61M	+14.1%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-15
Q3 2022	-$116M	-$9.5M	+$40.9M	+81.1%	Jul 1, 2022	Sep 30, 2022	10-K	2024-02-15
Q2 2022	-$157M	-$36M	+$11.1M	+23.6%	Apr 1, 2022	Jun 30, 2022	10-K	2024-02-15
Q1 2022	-$168M	-$37.9M	+$12.7M	+25.1%	Jan 1, 2022	Mar 31, 2022	10-K	2024-02-15
Q4 2021	-$181M	-$32.7M	-$24.7M	-306%	Oct 1, 2021	Dec 31, 2021	10-K	2023-02-28
Q3 2021	-$156M	-$50.4M	-$8.04M	-19%	Jul 1, 2021	Sep 30, 2021	10-K	2023-02-28
Q2 2021	-$148M	-$47.1M	-$20.3M	-75.5%	Apr 1, 2021	Jun 30, 2021	10-K	2023-02-28
Q1 2021	-$128M	-$50.5M	-$23.5M	-86.8%	Jan 1, 2021	Mar 31, 2021	10-K	2023-02-28
Q4 2020	-$104M	-$8.05M	+$26.8M	+76.9%	Oct 1, 2020	Dec 31, 2020	10-K	2022-02-28
Q3 2020	-$131M	-$42.3M	-$18.2M	-75.8%	Jul 1, 2020	Sep 30, 2020	10-K	2022-02-28
Q2 2020	-$113M	-$26.9M	-$9.72M	-56.7%	Apr 1, 2020	Jun 30, 2020	10-K	2022-02-28
Q1 2020	-$103M	-$27.1M	-$12.2M	-81.7%	Jan 1, 2020	Mar 31, 2020	10-K	2022-02-28
Q4 2019	-$90.9M	-$34.8M			Oct 1, 2019	Dec 31, 2019	10-K	2021-02-24
Q3 2019		-$24.1M			Jul 1, 2019	Sep 30, 2019	10-K	2021-02-24
Q2 2019		-$17.1M			Apr 1, 2019	Jun 30, 2019	10-K	2021-02-24
Q1 2019		-$14.9M			Jan 1, 2019	Mar 31, 2019	10-K	2021-02-24

* An asterisk sign (*) next to the value indicates that the value is likely invalid.